COSM · Cosmos Health Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the date of this filing.”View the 10-Q filed Aug 18, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COSM
this stock
Cosmos Health Inc.
|
$26.44M | -45.9% | +19.9% | — | 4.1% |
|
MCK
Mckesson Corp
|
$102.78B | +11.1% | +3.1% | 23.7 | 2.4% |
|
COR
Cencora, Inc.
|
$62.33B | -3.4% | +9.3% | 24.3 | 2.4% |
|
CAH
Cardinal Health Inc
|
$54.32B | +14.3% | +14.2% | — | 2.9% |
|
HSIC
Henry Schein Inc
|
$9.85B | +17.7% | +5.9% | 25.8 | 7.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COSM | -1.4% | +23.5% | -21.7% | +10.8% | -45.9% |
| SPY | -1.2% | -2.0% | +16.1% | -0.8% | +11.6% |
| vs SPY | -0.2% | +25.5% | -37.8% | +11.6% | -57.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.